献血不良反应严重程度分级标准及其应用进展*

doi:10.3969/j.issn.1671-2587.2024.06.021

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (6): 843-848.DOI: 10.3969/j.issn.1671-2587.2024.06.021

献血不良反应严重程度分级标准及其应用进展^*

杨俊鸿^1,2, 代华友¹, 杨冬燕¹, 黄霞^1,2

¹重庆市血液中心;
²中国输血协会血液安全监测专业委员会,重庆 400052

收稿日期:2024-03-07 出版日期:2024-12-20 发布日期:2024-12-20
通讯作者: 黄霞,主要从事血站质量管理和血液安全监测体系建立研究,（E-mail）xiahuangyy@163.com。杨冬燕,主要从事血站管理研究,（E-mail）576091430@qq.com。
作者简介:杨俊鸿,主要从事血液质量控制和血液安全监测体系建立研究,（E-mail）yangjunhong2013@163.com。
基金资助:
*本课题受重庆市输血协会华兰生物科研基金（No.CQSX-HL-202401）、重庆市九龙坡区技术预见与制度创新项目（No.2022-03-007-Z）资助

Received:2024-03-07 Online:2024-12-20 Published:2024-12-20

摘要/Abstract

摘要： 近年来,随着献血者安全监测工作的不断深入,献血不良反应作为献血者安全监测的核心内容之一得到了广泛关注。明确、统一的定义是开展献血不良反应监测的基础,也是不同单位、地区、国家之间进行数据比对的必要条件。其中严重程度分级是献血不良反应监测标准的重要内容之一。然而国内外输血医学界对于献血不良反应严重程度分级指标的设定存在较大的争议。因此,本文对国内外献血不良反应严重程度分级标准进展和应用情况进行综述,为我国完善献血不良反应严重程度分级指标提供参考。

关键词: 献血不良反应, 严重程度, 分级, 献血者安全

中图分类号:

R457

杨俊鸿, 代华友, 杨冬燕, 黄霞. 献血不良反应严重程度分级标准及其应用进展^*[J]. 临床输血与检验, 2024, 26(6): 843-848.

参考文献

[1] YANG J H,FAN D,XIE D F,et al.First donor haemovigilance system at a national level in China:establishment and improvement[J]. Vox Sang,2023,118(5):357-366.
[2] 杨俊鸿,陈敏,何涛,等. 我国全血献血者献血不良反应发生率Meta分析[J]. 中国输血杂志,2021,34(4):376-381.
[3] 杨俊鸿,黄霞,何涛,等. 献血不良反应监测进展[J]. 临床输血与检验,2020,22(5):556-560.
[4] Grading Severity of Blood Donor Adverse Events Tool. User Brochure AABB[EB/OL].[2024-2-29].https://www.aabb.org/docs/default-source/default-document-library/resources/severity-grading-tool-for-donor-adverse-events.pdf?sfvrsn=ff563263_6.
[5] 中国输血协会. 血液安全监测指南[S]. 2019.
[6] WIERSUM-OSSELTON J C,POLITIS C,RICHARDSON C,et al. Complications of blood donation reported to haemovigilance systems:analysis of eleven years of international surveillance[J].Vox Sang,2021,116(6):628-636.
[7] RADOVČIĆ M K,LJUBIČIĆ J,OČIĆ T,et al.Blood collection failures from a blood establishment perspective[J].Transfus Med,2021,31(2):88-93.
[8] THIJSEN A,THORPE R,DAVISON T E,et al.The vasovagal reaction experience among blood donors:a qualitative study of factors that affect donor return[J].Soc Sci Med,2021,282:114142.
[9] BRUNSON D C,BELANGER G A,SUSSMANN H,et al.Factors associated with first-time and repeat blood donation:adverse reactions and effects on donor behavior[J].Transfusion,2022,62(6):1269-1279.
[10] YOUNG P,CROWDER L,STEELE W,et al.Frequency of rare,serious donor reactions:international perspective[J].Transfusion,2021,61(6):1780-1788.
[11] WIERSUM-OSSELTON J,PRINSZE F,VAN DEN BREKEL E,et al.An intervention study for the prevention of vasovagal reactions and evaluating donors' experience:analysis of donors' return for subsequent donation[J].Vox Sang,2022,117(3):313-320.
[12] IBRAHIM N N,MOHD NOOR N H,ZULKAFLI Z.Prevalence and factors associated with vasovagal reaction among whole blood donors in hospital Universiti Sains Malaysia[J].Transfus Clin Biol,2023,30(2):238-243.
[13] International Society of Blood Transfusion, Working Party on Haemovigilance, Working Group on Complications Related to Blood Donation, European Haemovigilance Network.Standard for Surveillance of Complications Related to Blood Donation[EB/OL].[2024-2-29].http://www.isbt-web.org/members_only/files/society/StandardSurveillanceDOCO.pdf.
[14] Haemovigilance Network and the AABB Donor Haemovigilance Working Group.Standard for Surveillance of Complications Related to Blood Donation.ISBT working party on haemovigilance in collaboration with the International [EB/OL].(2014-12-11)[2024-2-29].https://www.isbtweb.org/isbt-working-parties/haemovigilance/resources.html.
[15] International Society of Blood Transfusion, Rationale for changes from 2008 to 2014 classification of adverse donor events[EB/OL].(2014-12-11) [2024-2-29].http://www.isbtweb.org/working-parties/haemovigilance/definitions.
[16] 郭永建. 国际输血协会献血并发症监测标准(2014年修订版)主要内容及其启示[J]. 中国输血杂志,2015,28(2): 223-229.
[17] 陈辉,徐健,郭瑾,等.国家卫生行业标准《献血不良反应分类指南》导读[J]. 中国输血杂志,2017,30(9):1080-1084.
[18] LAND K J,TOWNSEND M,GOLDMAN M,et al.International validation of harmonized definitions for complications of blood donations[J].Transfusion,2018,58(11):2589-2595.
[19] TOWNSEND M,KAMEL H,VAN BUREN N,et al.Development and validation of donor adverse reaction severity grading tool:enhancing objective grade assignment to donor adverse events[J].Transfusion,2020,60(6):1231-1242.
[20] US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology for Adverse Events Version 5.0.[EB/OL].(2017-11-27)[2024-2-29].http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
[21] RONEY J K,WHITLEY B E,JOHNSTON L,et al.Should adding pain,oxygen saturation and physical assessment to vital signs become the new standard of care for detecting blood transfusion reactions?[J].Vox Sang,2023,118(2):109-120.
[22] FREITES-MARTINEZ A,SANTANA N,ARIAS-SANTIAGO S,et al.Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies[J].Actas Dermosifiliogr (Engl Ed),2021,112(1):90-92.
[23] HUTCHESON K A,BARBON C E A,ALVAREZ C P,et al. Refining measurement of swallowing safety in the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) criteria:validation of DIGEST version 2[J].Cancer,2022,128(7):1458-1466.
[24] 陈辉,徐健,郭瑾,等. 国际输血行业标准《献血不良反应严重程度分级方法》主要内容及其启示[J]. 中国输血杂志,2022,35(1):124-127.
[25] 国家卫生计生委. 献血不良反应分类指南[S]. 2017.
[26] KAUR S,MITTAL K,KAUR R,et al.Reporting of delayed adverse donor reactions in whole blood donors:just the tip of an iceberg![J].Transfus Clin Biol,2022,29(2): 141-146.
[27] GUPTA A M,BAJPAI M.Delayed adverse reactions in whole blood donors:importance of active surveillance in identifying the missing gaps in the donor safety[J].Indian J Med Res,2023,157(1):30-36.
[28] MIKKELSEN C,PAARUP H M,BRUUN M T,et al.The new donor vigilance system in Denmark reveals regional differences in adverse reactions supposedly caused by variation in the registration[J].Vox Sang,2022,117(3):321-327.
[29] 刘黎燕,郑青青,徐雪梅. 《献血不良反应分类指南》运用实施体会[J]. 中国输血杂志,2020,33(12):1306-1308.
[30] 任爱民,居兵,刘媛媛,等. 多家血液中心献血不良反应监测工作开展情况分析[J]. 中国输血杂志,2022,35(4): 365-368.
[31] 张丽娜,王庆明,陆江洋,等. 石家庄地区无偿献血者不良反应及影响因素分析[J]. 华南预防医学,2022,48(8):977-980.
[32] PICCININI V,MARANO G,CATALANO L,et al.Vasovagal reactions in whole blood and apheresis donors:a cross-sectional study on donor haemovigilance data from 2016 to 2019 in Italy[J].Blood Transfus,2022,20(4):281-291.
[33] PAALVAST Y,PADILLA N D,BRUIJNS S,et al.Donor complication rates in whole blood,plasma and platelet donors:age versus experience[J].Transfusion,2024.
[34] BISHT A,ARORA S,PATIDAR G,et al.Knowledge assessment of a donor adverse reaction severity grading tool by the National Blood Donor Vigilance Programme of India[J].Vox Sang,2023,118(9):721-729.
[35] CHO J H,RAJBHANDARY S,VAN BUREN N L,et al.The safety of COVID-19 convalescent plasma donation:a multi-institutional donor hemovigilance study[J].Transfusion,2021,61(9):2668-2676.
[36] Affiliated to the Royal College of Pathologists.The2021 Annual SHOT Report[EB/OL].[2024-2-29].https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2021-FINAL-bookmarked-V3-November.pdf.
[37] Affiliated to the Royal College of Pathologists.The2022 Annual SHOT Report[EB/OL].[2024-2-29].https://www.shotuk.org/wp-content/uploads/myimages/SHOT-REPORT-2022-FINAL-Bookmarked-1.pdf.
[38] 中国输血协会血液安全监测专业委员会. 2020年血液安全监测报告[EB/OL]. (2021-9-8)[2024-2-29].http://www.cqsbt.org.cn/data/attachment/2023/01/08/380917001673152504.pdf.
[39] 中国输血协会血液安全监测专业委员会. 2021年血液安全监测报告[EB/OL]. (2022-9-15)[2024-2-29].http://www.cqsbt.org.cn/data/attachment/2023/01/08/060498001673152527.pdf.
[40] 中国输血协会血液安全监测专业委员会. 2022年血液安全监测报告[EB/OL]. (203-10-30)[2024-2-29].http://www.cqsbt.org.cn/data/attachment/2023/10/30/800519001698650805.pdf.

献血不良反应严重程度分级标准及其应用进展^*

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	谢东甫, 黄霞, 杨俊鸿, 孙洁, 张晰, 何涛. 国内外血液安全监测报告若干数据指标的比较与分析^*[J]. 临床输血与检验, 2023, 25(1): 16-20.
[2]	杨俊鸿, 胡文杰, 杨培, 邓莉, 黄霞, 徐永柱. 某血液中心开展献血不良反应监测实践及效果评价^*[J]. 临床输血与检验, 2023, 25(1): 21-25.
[3]	朱文钦, 陈齐, 曾嘉, 黄霞. 福州地区全血献血不良反应哨点监测情况分析[J]. 临床输血与检验, 2023, 25(1): 26-32.
[4]	李鹏, 袁玉荣, 张敏, 曾怡, 卢伟, 张莉, 黄霞. 献血相关血管迷走神经反应献血者血浆ET-1、NO检测和分析^*[J]. 临床输血与检验, 2023, 25(1): 44-47.
[5]	杨俊鸿, 许茜, 黄霞, 何涛. 英美两国献血者安全监测体系比较与启示^*[J]. 临床输血与检验, 2021, 23(5): 671-676.
[6]	杨俊鸿, 黄霞, 何涛, 李小红. 献血不良反应监测进展^*[J]. 临床输血与检验, 2020, 22(5): 556-560.
[7]	杨俊鸿, 胡文杰, 杨丹蓉, 何涛, 黄霞. 新型冠状病毒肺炎疫情期间献血相关血管迷走神经反应预防措施及监测效果分析[J]. 临床输血与检验, 2020, 22(4): 376-379.
[8]	庄健美, 谈春荣, 于文娟, 张金荣, 唐丽珍, 陈岩, 翟月萌, 何欣. 临床用血申请分级管理制度实施与效果评价[J]. 临床输血与检验, 2016, 18(3): 220-223.